These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

798 related items for PubMed ID: 18505175

  • 21. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M, Mühlberger N, Sroczynski G, Jaeger H, Wasem J, Siebert U.
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [Abstract] [Full Text] [Related]

  • 22. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy.
    Dheda K, Lampe FC, Johnson MA, Lipman MC.
    J Infect Dis; 2004 Nov 01; 190(9):1670-6. PubMed ID: 15478074
    [Abstract] [Full Text] [Related]

  • 23. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
    Omland LH, Weis N, Skinhøj P, Laursen A, Christensen PB, Nielsen HI, Møller A, Engsig F, Sørensen HT, Obel N.
    HIV Med; 2008 May 01; 9(5):300-6. PubMed ID: 18400077
    [Abstract] [Full Text] [Related]

  • 24. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy.
    Salzberger B, Hartmann P, Hanses F, Uyanik B, Cornely OA, Wöhrmann A, Fätkenheuer G.
    Infection; 2005 Oct 01; 33(5-6):345-9. PubMed ID: 16258865
    [Abstract] [Full Text] [Related]

  • 25. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.
    Jevtović Dj, Vanovac V, Veselinović M, Salemović D, Ranin J, Stefanova E.
    Biomed Pharmacother; 2009 Sep 01; 63(8):561-5. PubMed ID: 19026516
    [Abstract] [Full Text] [Related]

  • 26. Opportunistic infections and organ-specific diseases in HIV-1-infected children: a cohort study (1990-2006).
    Guillén S, García San Miguel L, Resino S, Bellón JM, González I, Jiménez de Ory S, Muñoz-Fernández MA, Navarro ML, Gurbindo MD, de José MI, Mellado MJ, Martín-Fontelos P, Gonzalez-Tomé MI, Martinez J, Beceiro J, Roa MA, Ramos JT, Madrid Group for Research on Pediatric HIV Infection.
    HIV Med; 2010 Apr 01; 11(4):245-52. PubMed ID: 20050937
    [Abstract] [Full Text] [Related]

  • 27. Five-year immunological outcome of highly active antiretroviral treatment in a clinical setting: results from a single HIV treatment centre.
    Schrooten W, Florence E, Dreezen C, Van Esbroeck M, Fransen K, Alonso A, Desmet P, Colebunders R, Kestens L, De Roo A.
    Int J STD AIDS; 2004 Aug 01; 15(8):523-8. PubMed ID: 15307962
    [Abstract] [Full Text] [Related]

  • 28. Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.
    Taha TE, Kumwenda J, Cole SR, Hoover DR, Kafulafula G, Fowler MG, Thigpen MC, Li Q, Kumwenda NI, Mofenson L.
    J Infect Dis; 2009 Nov 15; 200(10):1490-7. PubMed ID: 19832114
    [Abstract] [Full Text] [Related]

  • 29. The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART.
    Castor D, Vlahov D, Hoover DR, Berkman A, Wu YF, Zeller B, Brechtl J, Hammer SM.
    J Med Virol; 2009 Aug 15; 81(8):1323-35. PubMed ID: 19551816
    [Abstract] [Full Text] [Related]

  • 30. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
    Bihl F, Mosam A, Henry LN, Chisholm JV, Dollard S, Gumbi P, Cassol E, Page T, Mueller N, Kiepiela P, Martin JN, Coovadia HM, Scadden DT, Brander C.
    AIDS; 2007 Jun 19; 21(10):1245-52. PubMed ID: 17545700
    [Abstract] [Full Text] [Related]

  • 31. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
    El Amari EB, Toutous-Trellu L, Gayet-Ageron A, Baumann M, Cathomas G, Steffen I, Erb P, Mueller NJ, Furrer H, Cavassini M, Vernazza P, Hirsch HH, Bernasconi E, Hirschel B, Swiss HIV Cohort Study.
    AIDS; 2008 May 31; 22(9):1019-28. PubMed ID: 18520345
    [Abstract] [Full Text] [Related]

  • 32. Immune restoration disease in HIV-infected individuals receiving highly active antiretroviral therapy: clinical and immunological characteristics.
    de Boer MG, Kroon FP, Kauffmann RH, Vriesendorp R, Zwinderman K, van Dissel JT.
    Neth J Med; 2003 Dec 31; 61(12):408-12. PubMed ID: 15025416
    [Abstract] [Full Text] [Related]

  • 33. Effect of prolonged HAART on oral colonization with Candida and candidiasis.
    Yang YL, Lo HJ, Hung CC, Li Y.
    BMC Infect Dis; 2006 Jan 20; 6():8. PubMed ID: 16423306
    [Abstract] [Full Text] [Related]

  • 34. Characteristics of untreated AIDS-related cytomegalovirus retinitis. II. Findings in the era of highly active antiretroviral therapy (1997 to 2000).
    Holland GN, Vaudaux JD, Shiramizu KM, Yu F, Goldenberg DT, Gupta A, Carlson M, Read RW, Novack RD, Kuppermann BD, Southern California HIV/Eye Consortium.
    Am J Ophthalmol; 2008 Jan 20; 145(1):12-22. PubMed ID: 18154751
    [Abstract] [Full Text] [Related]

  • 35. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.
    Ekouevi DK, Coffie PA, Becquet R, Tonwe-Gold B, Horo A, Thiebaut R, Leroy V, Blanche S, Dabis F, Abrams EJ.
    AIDS; 2008 Sep 12; 22(14):1815-20. PubMed ID: 18753864
    [Abstract] [Full Text] [Related]

  • 36. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
    Isgrò A, Leti W, De Santis W, Marziali M, Esposito A, Fimiani C, Luzi G, Pinti M, Cossarizza A, Aiuti F, Mezzaroma I.
    Clin Infect Dis; 2008 Jun 15; 46(12):1902-10. PubMed ID: 18462177
    [Abstract] [Full Text] [Related]

  • 37. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
    Boyer S, March L, Kouanfack C, Laborde-Balen G, Marino P, Aghokeng AF, Mpoudi-Ngole E, Koulla-Shiro S, Delaporte E, Carrieri MP, Spire B, Laurent C, Moatti JP, Stratall ANRS 12110/ESTHER Study Group.
    Lancet Infect Dis; 2013 Jul 15; 13(7):577-86. PubMed ID: 23602084
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Effectiveness of antiretroviral treatment in a South African program: a cohort study.
    Fairall LR, Bachmann MO, Louwagie GM, van Vuuren C, Chikobvu P, Steyn D, Staniland GH, Timmerman V, Msimanga M, Seebregts CJ, Boulle A, Nhiwatiwa R, Bateman ED, Zwarenstein MF, Chapman RD.
    Arch Intern Med; 2008 Jan 14; 168(1):86-93. PubMed ID: 18195200
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 40.